(secondQuint)Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV.

 Twenty-four weeks of Daclatasvir plus Asunaprevir provided a high treatment efficacy in hepatitis C virus genotype 1b (HCV-1b) patients.

 Patients with non-structural protein 5A (NS5A) resistance associated variants (RAVs) would have an inferior response.

 The investigators anticipate that12 weeks of daclatasvir and asunaprevir plus ribavirin is highly effective for HCV Genotype 1b patients without baseline NS5A RAVs.

.

 Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV@highlight

A single-arm, multi-center study of HCV-1b patients without baseline non-structure protein (NS5A) resistance-associated variants.

 Daclatasvir (60mg/day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks will be prescribed.

